Why Apple is pausing sales of its latest watches in the U.S.

The International Trade Commission declared two months ago that Apple infringed on the patents of pulse oximeter company Masimo. 

December 18, 2023 Check out STAT+

Sponsored By

Caitlin O'Hara for STAT STAT+ | 'We've exhausted all avenues': A small biotech may give up on its ultra-rare disease drug over frustration with FDA Stealth BioTherapeutics, which is developing a therapy for Barth syndrome, has had an especially trying time seeking FDA approval. By Ed Silverman STAT+ | Apple pauses sales of latest watches in the U.S. after ITC decision Apple is pulling certain Apple Watches from the U.S. market to comply with an import ban issued by the International Trade Commission. By Lizzy Lawrence STAT+ | Here are the best biopharma CEOs of 2023 Nods to the CEOs behind some of this year's biggest biopharma deals and most exciting new drug treatments. By Adam Feuerstein Adobe STAT+ | Wegovy may have another helpful trick: fighting inflammation via the brain, study finds A study in mice finds GLP-1 weight loss drugs act in the brain to reduce inflammation, which may help explain why they benefit heart health. By Elaine Chen STAT+ | Biden administration asks judge to toss out Humana's Medicare Advantage audit lawsuit The Biden administration believes Humana has no standing to sue because new Medicare Advantage audits haven't taken place yet. By Bob Herman STAT+ | Prime Medicine, Mukherjee's Myeloid Therapeutics clash over genome-editing deal The biotech companies have filed competing arbitration claims over an agreement they signed in March 2022. By Jason Mast and Allison DeAngelis Adobe STAT+ | Structure Therapeutics GLP-1 pill cuts blood sugar, weight in early diabetes study Blockbuster GLP-1 drugs like Wegovy and Mounjaro are injected. Pills would make the medicines more accessible and attractive to patients. By Adam Feuerstein Opinion: Alzheimer's drug approvals show we need a reevaluation of patient advocacy The structure of patient advocacy groups and the haphazard manner in which they wield their immense power can get in the way of good science. By Jon Hu

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser